Healthcare News
Commercial Launch Announcement Marks a New Chapter for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) — FDA-Approved Preservative-Free Ketamine Now Being Sold, 17-Person National Sales Team Activated, Market Relationships Cover Approximately 80% of U.S. Ke
NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Also Received an $11 Million Dollar Award for Robotic Magnetic Stimulation with Pharma Treatment for Resistant Depression
A Landmark October 30th FDA Approval, Commercial Manufacturing Readiness, Two-Year Stability Results, and an $11.25 Million DARPA Research Contract Put NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) at an Important Turning Point in Its Growth
$SNNC acquires Majority Stake in New Joint Venture With Doc-Rx Opens the Door to Telehealth, U.S.-Made Peptides and an Ambitious Wellness Clinic Expansion Strategy
NRXP Reports Three Successfully Manufactured Commercial Lots, Two-Year Stability Data, and Commercially Releasable Supply Pending FDA Approval — While an $11.18 Million DARPA Contract Expands the Company's Research Opportunities
October 15 FDA Update Confirms Minor Labeling Changes Ahead of November 10 Goal Date, While an $11.18 Million DARPA Contract and Innovative Depression Research Expand the Company's Potential
New Meta META Reseller Status, Expanding Consumer Demand and Emerging Applications Across Humanoid Robotics, Military Training and Healthcare Position Virtuix $VTIX at the Intersection of Immersive Technology and Next-Generation Innovation
Healthcare technology and executive respondents cite integration, automation and cost reduction among key enterprise priorities
From "Diagnose and Treat" to "Predict, Alert and Intervene"—POMDOCTOR $POM. New AI-Powered Predictive Healthcare Vision Takes Center Stage in October 12 Announcement.
From AI-Powered Chronic Disease Management to "Hardware + AI + Payment," POMDOCTOR Is Building a Broader Digital Healthcare Infrastructure Platform
Today's landmark defense contract launches the FDA-approved SPARC-TMS trial while NRx simultaneously advances its preservative-free ketamine program, HOPE Therapeutics and an expanding CNS pipeline
Today's Proposed Combination Could Significantly Expand CDIX's Healthcare Footprint — While New Equity, Warrants and Exercise Activity Put the Capital Structure Squarely in Focus
Only 7% of healthcare organizations report difficulty recruiting early-career APPs, compared with 69% for experienced providers, as organizations expand APP utilization
With a potential Q4 commercial launch, expanding diagnostic opportunities, a major telehealth platform, veterinary oncology initiatives and a proposed Xycota acquisition, NexTel is positioning $MAJI around multiple potential growth catalysts
Today's GeNeuro patent milestone adds a potentially significant ALS opportunity to an already expanding NRx platform, while HOPE Therapeutics advances robotic TMS deployment and the company's preservative-free ketamine program moves closer to commercializ
NRx's HOPE Therapeutics is preparing to deploy Zeta Surgical's newly FDA-cleared robotic TMS technology in Florida, adding another major piece to a rapidly expanding neuropsychiatric platform while the company advances toward potential 2026 commercializat
With revenue shifting rapidly beyond China, positive net income returning, new international registrations, an expanding U.S. commercial footprint and a new IRE technology partnership, $BDMD is building a broader minimally invasive medical technology plat
NORCROSS, Ga. - -- While innovation in industries can lead to greater production and bottom lines, in healthcare it provides a more vital benefit: Better patient outcomes that save lives. Those ideas will be on display at the Healthcare Systems Process...
Q2 update reinforces the central NRXP investment thesis: preservative-free ketamine is moving toward commercialization while NRX-101, DARPA funding, HOPE Therapeutics and a stronger balance sheet create multiple potential catalysts.